- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.08. | Inhibikase taps commercial chief from Pfizer, Gilead to pave the way for PAH launch | 30 | FiercePharma | ||
| 19.08. | Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer | 287 | GlobeNewswire (Europe) | BOSTON and ATLANTA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify... ► Artikel lesen | |
| INHIBIKASE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 15.08. | Inhibikase Therapeutics GAAP EPS of -$0.11 | 1 | Seeking Alpha | ||
| 14.08. | Inhibikase Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.08. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.08. | Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity | 135 | GlobeNewswire (Europe) | BOSTON and ATLANTA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify... ► Artikel lesen | |
| 30.06. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.06. | Inhibikase Therapeutics files $300M mixed securities shelf | 1 | Seeking Alpha | ||
| 14.05. | Inhibikase Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 14.05. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 12.05. | Former Inhibikase leader launches new biotech for midstage Parkinson's asset | 1 | FierceBiotech | ||
| 14.04. | Inhibikase Therapeutics Appoints David McIntyre As CFO, Stock Up In Pre-market | - | RTTNews | ||
| 14.04. | Inhibikase Therapeutics appoints new CFO | 2 | Investing.com | ||
| 14.04. | Inhibikase Therapeutics appoints David McIntyre as CFO; shares rise | 1 | Seeking Alpha | ||
| 14.04. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 31.03. | H.C. Wainwright maintains Neutral on Inhibikase Therapeutics stock | 3 | Investing.com | ||
| 27.03. | Inhibikase Therapeutics GAAP EPS of -$1.16 | 1 | Seeking Alpha | ||
| 27.03. | Inhibikase Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 27.03. | Inhibikase Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 27.03. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ABBVIE | 189,40 | 0,00 % | Milliarden-Markt Psychedelika: AbbVie, Johnson & Johnson, Neural Therapeutics | ||
| TEVA | 15,500 | -0,96 % | Medincell Partner Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation | Regulatory News:
Medincell (Paris:MEDCL):
Data from the completed phase 3 SOLARIS trial to be presented at the 2025 Psych Congress Annual Meeting, taking place from September 17 21, 2025,... ► Artikel lesen | |
| EYEPOINT PHARMACEUTICALS | 11,470 | +1,41 % | EyePoint Pharmaceuticals, Inc.: EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WATERTOWN, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of... ► Artikel lesen | |
| ORGANIGRAM GLOBAL | 1,560 | +1,30 % | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA 02.04.2025 | The following instruments on XETRA do have their first trading 02.04.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 02.04.2025
Aktien
1 ROMEDLACNOR6 MedLife S.A.
2 CA29872T2092... ► Artikel lesen | |
| QUANTUM BIOPHARMA | 16,300 | +1,24 % | Quantum Biopharma Ltd: Quantum Biopharma granted product licence for Qlarity | ||
| ASTRIA THERAPEUTICS | 6,250 | +4,17 % | H.C. Wainwright hebt Kursziel für Astria Therapeutics auf 20 US-Dollar an | ||
| AMARIN | 12,900 | +2,38 % | Amarin Corporation plc: Amarin Reports Second Quarter 2025 Financial Results | -- European Partnership with Recordati Established to Maximize VAZKEPA® in Europe; Global Corporate Restructuring Implemented with Anticipated $70 Million in Operating Expense Savings Over Next 12... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 47,800 | +1,70 % | Why Nektar Therapeutics Stock Zoomed More Than 15% Higher Today | ||
| JAZZ PHARMACEUTICALS | 111,20 | +1,78 % | Piper Sandler reiterates Overweight rating on Jazz Pharmaceuticals stock | ||
| SELLAS LIFE SCIENCES | 1,392 | 0,00 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification | - Final Analysis Anticipated by Year-End Upon Occurrence of 80 Events - NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS'' or the... ► Artikel lesen | |
| XORTX THERAPEUTICS | 0,680 | -5,56 % | XORTX gibt 3-Millionen-USD-Platzierung bekannt | - Erlös wird für die Weiterentwicklung der XORTX-Programme zur Gichtbehandlung verwendet -
CALGARY, AB, 19. Mai 2025 / IRW-Press / XORTX Therapeutics Inc. ("XORTX" oder das "Unternehmen")... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 375,90 | +0,40 % | Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | CONSHOHOCKEN, Pa., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 44,460 | -0,22 % | BridgeBio: H.C. Wainwright bestätigt "Buy"-Rating wegen Potenzial von Encaleret | ||
| OPUS GENETICS | 1,306 | +0,46 % | Opus Genetics, Inc.: Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited... ► Artikel lesen | |
| RIGEL PHARMACEUTICALS | 29,000 | -2,03 % | Lisa Rojkjaer Enhances Portfolio With Rigel Pharmaceuticals Stock Options: $90K Acquired |
INHIBIKASE THERAPEUTICS INC gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell +5,84 % bei einem Aktienkurs von 1,630 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INHIBIKASE THERAPEUTICS INC finden Sie auf Wallstreet Online.